Concord Biotech Limited IPO : Key Information

Concord Biotech Limited IPO is set to launch on 4 August, 2023. The company initiated its business operations in 1984. The company is a biopharma company driven by Research and Development. It has its presence across the globe. Its supply is done in more than 70 countries like India, USA, Japan, Europe etc. 

Concord Biotech Limited IPO DETAILS

Concord Biotech Limited IPO is set to launch on 4 August, 2023. The subscription timeline extends till 8 August, 2023. The size for the IPO is 1551 Crore Rs. No Shares are issued through fresh issue mode. Shares issued through offer for sale mode are worth Rs 1551 Crore. The lot size is 20 shares and the price is 705 to 741 Rs per share. The company is going to get listed at both NSE and BSE. The face value per share is Rs.10 and this is a Book Built issue. The registrar for the company is Link Intime India Private Limited.

Tabular Description of Concord Biotech Limited IPO 

Concord Biotech Limited IPO : IMPORTANT DATES

Concord Biotech Limited IPO begins for subscription from 4 August, 2023. The IPO subscription would continue till 8 August, 2023. The allotment status for the shareholders who applied would come on 11 August, 2023. The refunds for the ones who did not get allotment would be initiated on 14 August, 2023. The DEMAT accounts of shareholders would be credited on 17 August, 2023. The listing of the company would be completed on 18 August 2023.

Concord Biotech Limited IPO : Lead Managers

The lead managers are :

• Citigroup Global Markets India Private Limited
• Kotak Mahindra Capital Company Limited
• Jefferies India Private Limited

The minimum lot size for the company is decided at 20 shares. This holding accounts to 14820 Rs.. The maximum lot size is decided at 260 shares. This amounts to 192660 Rs.. Hence the company’s final holdings would be set as :

OBJECTIVES FOR THE IPO

• IPO proceeds would be used for general corporate purposes.
• The company will use the IPO money for further working capital requirements.

COMPANY FINANCIALS

Concord Biotech Limited had an asset base of 4231 Crore Rs in 2021. This increased to 4515 Crore Rs in 2022. The mega boost in the asset base was witnessed in the year 2023. The asset base in the year 2023 was 5746 Crore Rs which more than 1200 Crore increased in comparison to the 2022 asset figure. The revenue of the firm was 511 Crore Rs in 2021. This increased by 20 crore Rs to 531 Crore Rs in 2022. The revenue in the year 2023 was boosted to 740 Crore Rs. This means that the asset and revenue of the firm witnessed a mega boost in the year 2023. 

The profit of the firm was recorded at 85 Crore Rs in 2021. However in the year 2022 the company’s profit decreased to 64 Crore Rs despite the increase in asset base and revenue. However in the year 2023 the profit of the company increased by 96 Crore Rs in comparison to the 2022 figures. This means that the profit was recorded at 150 Crore Rs in the year 2023.

PROS

• The company is a biopharma company driven by Research and Development. It has its presence across the globe. Its supply is done in more than 70 countries like India, USA, Japan, Europe etc. 

CONS

• The company works in a highly competitive segment.

Concord Biotech Limited IPO Application Process with Zerodha

It is very easy to apply for an IPO now if you have a DEMAT account with Zerodha. Follow the steps below for the same :

1. Logging into Zerodha console through its website or KITE platform. Clicking the IPO section present in the ORDER tab.
2. Click the Concord Biotech Limited IPO button and press the BID button.
3. Entering the details asked for like UPI ID, Quantity and price.
4. Submit the application form for the IPO.
5. Visiting the application of UPI for approving the transaction.

Now, applying for an IPO online is possible with most of the Discount and online brokers.